1194060-93-9

Basic information

• Product Name: ethyl 12-chloro-8-[(2,4-dimethoxyphenyl)methyl]-9-oxo-2,4, 8-triazatricyclo[8 .4.0.0²,⁶]tetradeca-1⁽¹⁴⁾,3,5,10,12-pentaene-5-carboxylate
• Synonyms: ethyl 12-chloro-8-[(2,4-dimethoxyphenyl)methyl]-9-oxo-2,4, 8-triazatricyclo[8 .4.0.0²,⁶]tetradeca-1⁽¹⁴⁾,3,5,10,12-pentaene-5-carboxylate
• CAS NO: 1194060-93-9
• Molecular Weight: 455.898
• Mol File: 1194060-93-9.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: ethyl 12-chloro-8-[(2,4-dimethoxyphenyl)methyl]-9-oxo-2,4, 8-triazatricyclo[8 .4.0.0²,⁶]tetradeca-1⁽¹⁴⁾,3,5,10,12-pentaene-5-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 12-chloro-8-[(2,4-dimethoxyphenyl)methyl]-9-oxo-2,4, 8-triazatricyclo[8 .4.0.0²,⁶]tetradeca-1⁽¹⁴⁾,3,5,10,12-pentaene-5-carboxylate(1194060-93-9)
• EPA Substance Registry System: ethyl 12-chloro-8-[(2,4-dimethoxyphenyl)methyl]-9-oxo-2,4, 8-triazatricyclo[8 .4.0.0²,⁶]tetradeca-1⁽¹⁴⁾,3,5,10,12-pentaene-5-carboxylate(1194060-93-9)

Safety Data

• Hazardous Substances Data: 1194060-93-9(Hazardous Substances Data)

Upstream product

• 613-45-6 2,4-Dimethoxybenzaldehyde 
• 20839-79-6 (2,4-dimethoxy-benzylamino)-acetic acid 
• 95218-34-1 ethyl 2-{[(2,4-dimethoxyphenyl)methyl]amino}acetate 
• 2999-46-4 Ethyl isocyanoacetate 
• 20781-20-8 2,4-Dimethoxybenzylamine 

Relevant articles and documents

α5GABA AGONIST POLYMORPHS AND METHODS OF USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT

The invention relates to crystalline forms of a GABAA α5 agonist, pharmaceutical compositions and combinations comprising these crystalline forms, their use in methods of treatment of cognitive impairment associated with disorders of the central nervous system (CNS), cognitive impairment associated with brain cancer, brain cancer itself or psychosis of Parkinson's disease, as well as processes for the production of crystalline forms.

BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT

This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a α5-containing GABAA receptor agonist (e.g., a α5-containing GABAA receptor positive allosteric modulator) as described herein in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease(AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction. It also relates to the use of a α5-containing GABAA receptor agonist (e.g., a α5-containing GABAA receptor positive allosteric modulator) as described herein in treating brain cancers (including brain tumors, e.g., medulloblastomas), and cognitive impairment associated therewith.